Esperion Therapeutics, Inc.

Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.

ESPR | NDAQ

Overview

Corporate Details

ISIN(s):: US29664W1053
LEI:
Country:: United States of America
Address:: 3891 RANCHERO DRIVE, SUITE 150, 48108 ANN ARBOR
Website:: https://www.esperion.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Esperion Therapeutics, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk. The company's core products are based on a novel mechanism of action, being the first to bring an ATP Citrate Lyase (ACLY) inhibitor to market. These treatments are approved in the U.S. and Europe, addressing significant unmet needs in cardiovascular disease management, particularly for patients with statin intolerance. Esperion utilizes commercial partnerships to enable global access to its medicines while advancing a pipeline focused on next-generation inhibitors for life-threatening diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Esperion Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Esperion Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Esperion Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Armata Pharmaceuticals, Inc. Developing bacteriophage therapeutics for antibiotic-resistant infections.	United States of America	ARMP
AroCell AB Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.	Sweden	AROC
ArriVent BioPharma, Inc. A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.	United States of America	AVBP
ARROWHEAD PHARMACEUTICALS, INC. Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.	United States of America	ARWR
ARS Pharmaceuticals, Inc. Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.	United States of America	SPRY
ARTELO BIOSCIENCES, INC. Develops lipid-signaling therapeutics for cancer, pain, anxiety, and depression.	United States of America	ARTL
Artiva Biotherapeutics, Inc. Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.	United States of America	ARTV
Ascelia Pharma Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.	Sweden	ACE
Ascendis Pharma A/S Biopharma using proprietary TransCon® tech to develop therapies for rare diseases & oncology.	United States of America	ASND
ASCENTAGE PHARMA GROUP INTERNATIONAL Biopharma developing small-molecule drugs for cancer, HBV, and age-related diseases.	United States of America	AAPG